Does adalimumab cause a higher rate of paradoxical psoriasis compared to infliximab in patients with CD

What is known

- Both agents are reported to cause paradoxical psoriasis in Crohn's disease, documented in case reports for adalimumab ¹ and infliximab ². - Reviews describe new-onset psoriasis across infliximab, adalimumab, and etanercept, without quantifying comparative rates ³.

What is unknown / caveats

- The retrieved evidence does not answer whether adalimumab causes a higher rate of paradoxical psoriasis than infliximab - No source directly compares the two rates - The adalimumab and infliximab evidence is limited to case reports

## References

1. Alenizi D. Adalimumab induced psoriasis in a Crohn's disease patient: A case report. J Pak Med Assoc. 2024. PMID: 39028072.

2. Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease. Biologics. 2018. PMID: 30050284.

3. Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol. 2013. PMID: 23986169.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._